CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接头介导 CAR 的 CAR-T 疗法模块化控制研究进展
英文原题：Advances in modular control of CAR-T therapy with adapter-mediated CARs.
查看英文原题
Advances in modular control of CAR-T therapy with adapter-mediated CARs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
蛋白质工程为基于 T 细胞的免疫治疗领域的成功做出了贡献，包括嵌合抗原受体（CAR）T 细胞疗法。CAR-T 细胞疗法已成为癌症免疫治疗的支柱，通过靶向 B 细胞抗原 CD19，在 B 细胞恶性肿瘤中展现出临床疗效。当前的基因编辑技术对 CAR-T 细胞活性的安全控制有限，这为在患者中控制 CAR-T 细胞带来了障碍。另一种方法是通过工程化 CAR 使其结合可溶性衔接分子来控制 CAR-T 细胞活性，这些衔接分子引导 CAR-T 细胞与靶细胞之间的相互作用。这种衔接分子介导方法的灵活性克服了传统 CAR-T 细胞的固定特异性，从而能够靶向多种细胞类型。在此，我们描述衔接分子 CAR-T 技术，以及这些方法如何凸显蛋白质工程在 T 细胞疗法可编程工具设计中日益增长的作用。
展开英文摘要原文
Protein engineering has contributed to successes in the field of T cell-based immunotherapy, including chimeric antigen receptor (CAR) T cell therapy. CAR T cell therapy has become a pillar of cancer immunotherapy, demonstrating clinical effectiveness against B cell malignancies by targeting the B cell antigen CD19. Current gene editing techniques have limited safety controls over CAR T cell activity, which presents a hurdle for control of CAR T cells in patients.
Alternatively, CAR T cell activity can be controlled by engineering CARs to bind soluble adapter molecules that direct the interaction between the CAR T cell and target cell. The flexibility in this adapter-mediated approach overcomes the rigid specificity of traditional CAR T cells to allow targeting of multiple cell types.
Here we describe adapter CAR T technologies and how these methods emphasize the growing role of protein engineering in the design of programmable tools for T cell therapies.
论文信息
- 作者
- McCue AC、Yao Z、Kuhlman B
- 第一作者单位
- Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: acmccue@unc.edu.United States
- 通讯作者单位
- Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA. Electronic address: bkuhlman@email.unc.edu.United States
- 文献类型
- 综述 · 美国 NIH 资助研究
- 期刊
- Advanced drug delivery reviews2022 Aug
- 原文标识
- PubMed 35618140 · DOI 10.1016/j.addr.2022.114358
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →